期刊
FUTURE ONCOLOGY
卷 16, 期 1, 页码 4251-4264出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2019-0633
关键词
DCC-2618; gastrointestinal stromal tumor; KIT; PDGFRA; Phase III trial; receptor tyrosine kinase; ripretinib; sarcoma; targeted therapy; tyrosine kinase inhibitor
类别
资金
- Deciphera Pharmaceuticals, LLC, MA, USA
- Novartis
- Incyte
- Blueprint Medicines
- Deciphera Pharmaceuticals, LLC
- Bayer
- Eli Lilly
- Roche
- Pharmamar
- Daiichi Sankyo
- Five Prime
- Eisai
- Debio
- Boehringer Ingelheim
- Pfizer
- Amgen
- Teva
- CoBioRes NV
- Exelixis
- G1 Therapeutics
- Plexxikon
- Arog Pharmaceuticals
- Gradalis
- Genmab
- Merck Serono
- Bristol-Myers Squibb
- AstraZeneca
- Specialized Therapeutics
- Baxalta/Shire
Ripretinib (DCC-2618) is a novel, type II tyrosine switch control inhibitor designed to broadly inhibit activating and drug-resistant mutations in KIT and PDGFRA. Ripretinib has emerged as a promising investigational agent for the treatment of gastrointestinal stromal tumor owing to targeted inhibition of secondary resistance mutations that may develop following treatment with prior line(s) of tyrosine kinase inhibitors. Here we describe the rationale and design of intrigue (NCT03673501), a global, randomized (1:1), open-label, Phase III study comparing the safety and efficacy of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor following imatinib. The primary end point is progressionfree survival and key secondary objectives include objective response rate and overall survival.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据